Legal Representation
Attorney
Steven A. Abreu
USPTO Deadlines
Next Deadline
1586 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-11-14)
Due Date
November 14, 2029
Grace Period Ends
May 14, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 6, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Nov 14, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Nov 14, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Oct 13, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Oct 12, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Oct 12, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Oct 12, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Oct 12, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Oct 12, 2023 | SNEA | W | SU-EXAMINER'S AMENDMENT WRITTEN |
| Aug 23, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 23, 2023 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Aug 23, 2023 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN |
| Aug 10, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Aug 7, 2023 | IUAF | S | USE AMENDMENT FILED |
| Aug 7, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Feb 9, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 8, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Feb 8, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jan 23, 2023 | EXT5 | S | SOU EXTENSION 5 FILED |
| Jan 23, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 12, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jul 8, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Jul 8, 2022 | EXT4 | S | SOU EXTENSION 4 FILED |
| Jul 8, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 17, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 15, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Feb 15, 2022 | EXT3 | S | SOU EXTENSION 3 FILED |
| Feb 15, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 5, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 3, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Aug 3, 2021 | EXT2 | S | SOU EXTENSION 2 FILED |
| Aug 3, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 12, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 10, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Feb 10, 2021 | EXT1 | S | SOU EXTENSION 1 FILED |
| Feb 10, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 18, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jun 23, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jun 23, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jun 3, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| May 15, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 14, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 13, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 13, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Apr 1, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Apr 1, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Apr 1, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Feb 20, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Feb 20, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Feb 20, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN |
Detailed Classifications
Class 005
Biomedical compounds for medical purposes, namely, peptides, stapled peptides, and synthetic peptides, all comprised of amino acids, for the treatment of cancer, inflammatory conditions, immunological disorders, cardiovascular conditions, infectious diseases, and neurological conditions; biomedical compounds for medical purposes, namely, miniproteins, and cell-penetrating miniproteins (CPMPs) arrays for diagnosing cancer, inflammatory conditions, immunological disorders, cardiovascular conditions, infectious diseases, and neurological conditions
First Use Anywhere:
May 22, 2023
First Use in Commerce:
May 22, 2023
Classification
International Classes
005